Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2016–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $35M | $26M | $10M | $64M | $356M | $71M | $47M | — | — |
| Enterprise Value | $23M | $56M | $38M | $19M | $67M | $390M | $87M | $16M | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 1915.54 | 54.62 | — | — |
| P/B Ratio | — | — | — | 0.37 | 1.27 | — | — | 0.66 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 2345.86 | 18.40 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | — | — | — | — | — | — | -275732.4% | -8810.0% | -5798.2% | — |
| Net Profit Margin | — | — | — | — | — | — | -278729.7% | -8867.2% | -5788.6% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -355.4% | -113.6% | -182.3% | — | -454.5% | -138.7% | -94.6% | -59.4% |
| ROA | -69.9% | -69.9% | -82.4% | -56.1% | -147.3% | -177.7% | -166.8% | -106.6% | -79.8% | -50.0% |
| ROIC | -117.8% | -117.8% | -163.7% | -50.5% | -101.8% | — | -512.9% | -161.4% | -153.1% | — |
| ROCE | -94.1% | -94.1% | -134.6% | -44.6% | -70.4% | — | -274.2% | -122.2% | -94.5% | -58.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 1.08 | 0.61 | — | — | 0.18 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 0.32 | 0.06 | — | — | -0.44 | -0.21 | -1.09 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -17.69 | -15.36 | -2.40 | -118.26 | -178.77 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | 1.41 | 1.89 | 6.89 | 6.43 | 0.51 | 0.25 | 6.93 | 6.20 | 6.13 |
| Quick Ratio | 1.41 | 1.41 | 1.89 | 6.89 | 6.43 | 0.51 | 0.25 | 7.57 | 6.20 | 6.13 |
| Cash Ratio | 1.37 | 1.37 | 1.77 | 6.71 | 6.29 | 0.35 | 0.13 | 6.92 | 5.50 | 5.88 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.01 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 10959.86 | 302.84 | 365.72 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $20M | $13M | $12M | $11M | $24M | $1M | $631574 | $549150 | $14M |
Binary regulatory approval dependence
As reported in recent financial statements, Iterum's ROIC has remained deeply negative, reaching -35.7% in 2025Q3, which highlights the company's ongoing struggle to generate meaningful returns on invested capital while it continues to fund the high-cost development of its lead antibiotic candidate, sulopenem.
The consistent decay in ROIC, which plummeted to -68.5% in 2024Q1, suggests that the company is currently destroying shareholder value through its intensive R&D spending. Investors should monitor whether the potential commercialization of sulopenem can reverse this trend, as the current negative returns are structural rather than cyclical.
Based on 2025Q3 data, the company's cash conversion cycle remains highly extended at 835 days, reflecting significant challenges in managing working capital as the firm transitions from a clinical-stage entity to a nascent commercial operation with limited inventory turnover and high accounts payable reliance.
The extreme volatility in the cash conversion cycle, including a massive spike in days payable outstanding, suggests that the company is managing its limited liquidity by delaying payments to suppliers. This strategy appears unsustainable and may indicate underlying pressure on the firm's ability to maintain operational continuity.
According to the 2025Q3 balance sheet, the current ratio of 2.13 provides a superficial appearance of stability, yet this metric masks the company's precarious cash position when evaluated against the ongoing quarterly burn rate and the significant debt obligations that continue to pressure the firm.
While the quick ratio of 1.96 suggests that the company holds sufficient liquid assets to cover immediate liabilities, the lack of recurring revenue makes this liquidity highly sensitive to any further delays in regulatory approval. Investors should remain cautious, as the current liquidity buffer may be insufficient to support a full-scale commercial launch.
As indicated by the company's financial profile, the use of traditional P/E or EV/EBITDA multiples is fundamentally flawed for Iterum, as these metrics obscure the binary nature of the firm's value, which is tied to regulatory milestones rather than current earnings or operational cash flow.
Analysts should instead focus on the 'cash runway vs. PDUFA date' ratio, as this provides a more accurate assessment of the company's survival risk. Relying on standard valuation multiples in this context may lead to a significant mispricing of the firm's true risk-adjusted potential.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ITRM stock.
Iterum Therapeutics plc's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Iterum Therapeutics plc is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.